EP1804810A4 - Verfahren unter verwendung von glycosaminoglykanen zur behandlung von nierenerkrankungen - Google Patents

Verfahren unter verwendung von glycosaminoglykanen zur behandlung von nierenerkrankungen

Info

Publication number
EP1804810A4
EP1804810A4 EP05807269A EP05807269A EP1804810A4 EP 1804810 A4 EP1804810 A4 EP 1804810A4 EP 05807269 A EP05807269 A EP 05807269A EP 05807269 A EP05807269 A EP 05807269A EP 1804810 A4 EP1804810 A4 EP 1804810A4
Authority
EP
European Patent Office
Prior art keywords
glycosaminoglycans
treatment
methods
kidney disease
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05807269A
Other languages
English (en)
French (fr)
Other versions
EP1804810A1 (de
Inventor
Michael Spero
Michael S Weiss
Jeffrey B Kopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of EP1804810A1 publication Critical patent/EP1804810A1/de
Publication of EP1804810A4 publication Critical patent/EP1804810A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05807269A 2004-10-01 2005-10-03 Verfahren unter verwendung von glycosaminoglykanen zur behandlung von nierenerkrankungen Withdrawn EP1804810A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61547204P 2004-10-01 2004-10-01
US62233204P 2004-10-26 2004-10-26
PCT/US2005/035790 WO2006039709A1 (en) 2004-10-01 2005-10-03 Methods using glycosaminoglycans for the treatment of kidney disease

Publications (2)

Publication Number Publication Date
EP1804810A1 EP1804810A1 (de) 2007-07-11
EP1804810A4 true EP1804810A4 (de) 2008-02-27

Family

ID=36142893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05807269A Withdrawn EP1804810A4 (de) 2004-10-01 2005-10-03 Verfahren unter verwendung von glycosaminoglykanen zur behandlung von nierenerkrankungen

Country Status (6)

Country Link
EP (1) EP1804810A4 (de)
JP (1) JP2008515807A (de)
AU (1) AU2005292202A1 (de)
CA (1) CA2583079A1 (de)
IL (1) IL182353A0 (de)
WO (1) WO2006039709A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616230A1 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
WO2007125385A2 (en) 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
CA2851513A1 (en) * 2011-10-11 2013-04-18 Drp Biomedical, Inc. Method for treating acute kidney injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046237A1 (en) * 1997-04-16 1998-10-22 The United States of America, represented by The Secretary, Department of Health & Human Services Method of treating chronic progressive vascular scarring diseases
WO2002100417A2 (en) * 2001-06-12 2002-12-19 Keryx Biopharmaceuticals Inc. Use of glycosaminoglycans for the treatment of hiv-associated nephropathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046237A1 (en) * 1997-04-16 1998-10-22 The United States of America, represented by The Secretary, Department of Health & Human Services Method of treating chronic progressive vascular scarring diseases
WO2002100417A2 (en) * 2001-06-12 2002-12-19 Keryx Biopharmaceuticals Inc. Use of glycosaminoglycans for the treatment of hiv-associated nephropathy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRCEVSKA L ET AL: "Low-Molecular Weight Heparin Treatment in Patients with Glomerular Sclerosis", CLINICAL NEPHROLOGY, DUSTRI VERLAG, NUENCHEN-DEISENHOFEN, DE, vol. 54, no. 3, 3 November 2000 (2000-11-03), pages 14 - 17, XP002996199, ISSN: 0301-0430 *
KRZOSSOK S ET AL: "Treatment of proteinuria with low-molecular-weight heparin after renal transplantation", TRANSPLANT INTERNATIONAL 2004 GERMANY, vol. 17, no. 8, 2004, pages 468 - 472, XP002463613, ISSN: 0934-0874 *
LINES D R ET AL: "Focal glomerulosclerosis treated with heparin.", ARCHIVES OF DISEASE IN CHILDHOOD JUN 1989, vol. 64, no. 6, June 1989 (1989-06-01), pages 855 - 857, XP008087042, ISSN: 1468-2044 *
See also references of WO2006039709A1 *

Also Published As

Publication number Publication date
EP1804810A1 (de) 2007-07-11
WO2006039709A1 (en) 2006-04-13
IL182353A0 (en) 2008-04-13
AU2005292202A1 (en) 2006-04-13
JP2008515807A (ja) 2008-05-15
CA2583079A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
HK1248630A1 (zh) 用於組合式超聲治療的系統
EP1928453A4 (de) Verfahren und zusammensetzungen zur prävention und behandlung von nierenerkrankungen
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
ZA200700281B (en) Dihydropteridinones for the treatment of cancer diseases
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1755670A4 (de) Verfahren zur behandlung von gefässerkrankungen
GB2430002B (en) Well treatment
EP1768656A4 (de) Behandlung von augenkrankheit
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
GB0400802D0 (en) Compounds for the treatment of disease
GB0426196D0 (en) Methods of treatment
GB0424085D0 (en) Well treatment
ZA200606780B (en) Compounds for the treatment of diseases
HU0401379D0 (en) Process for the preparation of risperidon
GB0428291D0 (en) Methods of regenerating NOx-Absorbent
GB0516753D0 (en) Molecular methods for the treatment of disease
GB0415352D0 (en) Compounds for the treatment of disease
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases
GB0516619D0 (en) Methods of treatment of neoplastic disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 13/12 20060101ALI20080117BHEP

Ipc: A61K 31/726 20060101ALI20080117BHEP

Ipc: A61K 31/70 20060101AFI20060828BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090505